| The anaplastic lymphoma kinase in the pathogenesis of cancer R Chiarle, C Voena, C Ambrogio, R Piva, G Inghirami Nature Reviews Cancer 8 (1), 11-23, 2008 | 1102 | 2008 |
| Nucleotide-resolution DNA double-strand break mapping by next-generation sequencing N Crosetto, A Mitra, MJ Silva, M Bienko, N Dojer, Q Wang, E Karaca, ... Nature methods 10 (4), 361-365, 2013 | 580 | 2013 |
| Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells R Chiarle, Y Zhang, RL Frock, SM Lewis, B Molinie, YJ Ho, DR Myers, ... Cell 147 (1), 107-119, 2011 | 554 | 2011 |
| Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target R Chiarle, WJ Simmons, H Cai, G Dhall, A Zamo, R Raz, JG Karras, ... Nature medicine 11 (6), 623-629, 2005 | 546 | 2005 |
| Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death A Zamo, R Chiarle, R Piva, J Howes, Y Fan, M Chilosi, DE Levy, ... Oncogene 21 (7), 1038-1047, 2002 | 498 | 2002 |
| Role of the F-box protein Skp2 in lymphomagenesis E Latres, R Chiarle, BA Schulman, NP Pavletich, A Pellicer, G Inghirami, ... Proceedings of the National Academy of Sciences 98 (5), 2515-2520, 2001 | 402 | 2001 |
| The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo FA Karreth, M Reschke, A Ruocco, C Ng, B Chapuy, V Léopold, ... Cell 161 (2), 319-332, 2015 | 354 | 2015 |
| FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas S Duan, L Cermak, JK Pagan, M Rossi, C Martinengo, PF Di Celle, ... Nature 481 (7379), 90-93, 2012 | 339 | 2012 |
| The STAT3 isoforms α and β have unique and specific functions D Maritano, ML Sugrue, S Tininini, S Dewilde, B Strobl, XP Fu, ... Nature immunology 5 (4), 401-409, 2004 | 333 | 2004 |
| KRAS dimerization impacts MEK inhibitor sensitivity and oncogenic activity of mutant KRAS C Ambrogio, J Köhler, ZW Zhou, H Wang, R Paranal, J Li, M Capelletti, ... Cell 172 (4), 857-868. e15, 2018 | 327 | 2018 |
| NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors R Chiarle, JZ Gong, I Guasparri, A Pesci, J Cai, J Liu, WJ Simmons, ... Blood, The Journal of the American Society of Hematology 101 (5), 1919-1927, 2003 | 318 | 2003 |
| Substitutions at codon 22 of Alzheimer's Aβ peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells L Miravalle, T Tokuda, R Chiarle, G Giaccone, O Bugiani, F Tagliavini, ... Journal of Biological Chemistry 275 (35), 27110-27116, 2000 | 299 | 2000 |
| Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma R Chiarle, LM Budel, J Skolnik, G Frizzera, M Chilosi, A Corato, G Pizzolo, ... Blood, The Journal of the American Society of Hematology 95 (2), 619-626, 2000 | 292 | 2000 |
| Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology RB Blasco, E Karaca, C Ambrogio, TC Cheong, E Karayol, VG Minero, ... Cell reports 9 (4), 1219-1227, 2014 | 249 | 2014 |
| CD30 in normal and neoplastic cells R Chiarle, A Podda, G Prolla, J Gong, GJ Thorbecke, G Inghirami Clinical immunology 90 (2), 157-164, 1999 | 204 | 1999 |
| Mechanisms that promote and suppress chromosomal translocations in lymphocytes M Gostissa, FW Alt, R Chiarle Annual review of immunology 29 (1), 319-350, 2011 | 202 | 2011 |
| Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and Bcl2A1 as critical target genes R Piva, E Pellegrino, M Mattioli, L Agnelli, L Lombardi, F Boccalatte, ... The Journal of clinical investigation 116 (12), 3171-3182, 2006 | 199 | 2006 |
| Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing J Tao, DE Bauer, R Chiarle Nature Communications 14 (1), 212, 2023 | 195 | 2023 |
| Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas R Piva, R Chiarle, AD Manazza, R Taulli, W Simmons, C Ambrogio, ... Blood 107 (2), 689-697, 2006 | 179 | 2006 |
| New and old functions of STAT3: a pivitol target for individualized treatment of cancer G Inghirami, R Chiarle, WJ Simmons, R Piva, K Schlessinger, DE Levy Cell cycle 4 (9), 1131-1133, 2005 | 175 | 2005 |
